

NEWS RELEASE

Contact: Bob Cardon, Dynatronics Corp.
800-874-6251 or 801-568-7000

Dynatronics Ships New Dynatron X5 Therapy Unit

Salt Lake City, Utah (July 5, 2007) – Dynatronics Corporation (NASDAQ: DYNT) today announced that it has begun shipping the new Dynatron X5 soft tissue oscillation therapy unit.

Soft tissue oscillation therapy has been used in Europe for over 15 years, yet is relatively new to the United States market. The X5 creates an electrostatic field within the patient, resulting in a highly effective treatment for pain.

“Orders for the new Dynatron X5 surpassed our initial projections,” reported Kelvyn H. Cullimore Jr., president of Dynatronics. “We are pleased with the market acceptance of this new modality and look forward to the positive impact it is projected to have on the company’s performance due to the X5’s attractive margins.”

“This innovative technology gives practitioners an effective new way to treat their patients’ pain,” said Larry K. Beardall, executive vice president of sales and marketing. “Not only does it reduce pain, but it decreases muscle soreness and muscle spasm while also improving circulation.”

“Treatments with this new therapy are fast and easy to apply,” said Stephen Guffey, RPT, PhD. “My patients love the results and how comfortable the treatments are.”

Dynatronics expects to announce a return to profitability in the fourth quarter ended June 30, 2007 as a result of the X5 introduction.

“With the recently announced dealer acquisitions and the introduction of this new product, we believe fiscal 2008 will be a very good year for Dynatronics,” added Cullimore.

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, pain management, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets.

This press release contains forward-looking statements. Those statements include references to the company’s expectations, anticipated growth in sales, profitability in future periods and similar statements. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company’s products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, FDA clearance of new products, growth in the physical medicine industry, competitive factors, availability of third-party component parts and products, inventory risks due to shifts in market demand, changes in product mix, market demand for the company’s products, and the risk factors listed from time to time in the company’s SEC reports, including, but not limited to the report on Form 10-KSB for the year ended June 30, 2006.

###